iohexol


Also found in: Wikipedia.

i·o·hex·ol

(ī'ō-heks'ol),
A monomeric, nonionic, water-soluble, low osmolar radiographic contrast medium for urography or angiography. Used intrathecally and intravascularly.

iohexol

A contrast medium used to assist in X-ray examination of the spinal canal, the arteries and the urinary system. The drug is on the WHO official list.
References in periodicals archive ?
Ligand announced top line results from a Phase 1 clinical trial of its internal Captisol-enabled, or CE, Iohexol program.
Data were acquired before and after administration of iodinated contrast material (2 mL/kg IV; iohexol 300 mg/mL; Omnipaque, GE Healthcare, Marlborough, MA, USA).
M2 PHARMA-May 7, 2019-Ligand Completes Enrollment of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Encephalopathy has been documented after administration of iopromide, (9,10) iohexol, (11) ioxilan, (4) and metrizamide.
Contrast-enhanced helical CT scans (collimation, 4x2.5 mm; slice thickness, 5 mm; range of reconstruction, 5 mm; section 64, Aquilion; Toshiba Medical Systems, Tokyo) were obtained 65 s after the administration of 100 mL Iohexol (Omnipaque 300) at a rate of 3 mL/s.
Omnipaque (Iohexol 350mg I/ml) X-ray contrast agent was administered to all patients.
On a visit in 2013, the patient was evaluated with CT urogram without and with IV contrast (150cc IV iohexol 300, Figure 2).
Once when the position was confirmed, 1 ml of non-ionic contrast agent (Iohexol, omnipaque 350 mgl m[L.sup.-1]) was injected, and a fluoroscopic image was obtained to assess the spread of the dye (Figure 3).
VFI-based mGFR values were compared with values obtained by measuring iohexol plasma disappearance in a study involving 16 adults with normal kidney function, eight with chronic kidney disease (CKD) stage 3, and eight with CKD stage 4.
Overall, 95 mL intravenous iodinated-contrast agent (iohexol, Omnipaque 350 mg/mL, GE Healthcare, Princeton, New Jersey) was administered to visualize the coronary arteries.
Other methods use radiolabeled isotopes or nonradioactive contrast agents such as Cr51-EDTA, iohexol, and iothalamate; nonetheless, not only can these methods be difficult to perform but also they are invasive and not available in all laboratories or hospitals.
Enhanced scan was obtained using dual-tube high-pressure syringe injection of the nonionic contrast agent iohexol (350 mgI/ml, Yangtze River Pharmaceutical Company) in the amount of 1.5ml/kg, with injection flow rate of 2.5 ml/s.